Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA V: Final Recommendations Fund Proposals In Two Of Three Tiers

Executive Summary

Industry and FDA agreed to a recommendation package for the PDUFA V commitment letter after dividing agency proposals into three tiers and funding two.

You may also be interested in...



PDUFA VI: Innovative Trial Design Proposal Includes Modeling, Simulation

Both ideas also will require more FDA expertise, agency tells industry.

PDUFA VI: FDA Proposes Expanding Sentinel, Real-World Safety Data Sources

Growth of post-market surveillance system also may require more resources.

Biomarkers: FDA Working To Define 'Reasonably Likely To Predict' Standard

CDER Director Woodcock says agency should write down its definition of a surrogate endpoint, but industry and academics will have to help with requirements for biomarker approval.

Related Content

Topics

UsernamePublicRestriction

Register

PS053359

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel